Biocept reports plans to price initial public offering of common stock

Company will sell common stock through bookrunner Aegis Capital

By Devika Patel

Knoxville, Tenn., Sept. 23 - Biocept, Inc. will price its initial public offering of common stock with a 45-day greenshoe, according to an S-1 filing made Monday with the Securities and Exchange Commission.

Aegis Capital Corp. is the bookrunning manager.

Proceeds will be used to hire sales and marketing personnel and support increased sales and marketing activities, acquire equipment, implement automation and scale capabilities to prepare for significant test volume, satisfy deferred salary obligations, for research and development, clinical utility studies, general corporate purposes, operations and business expansion.

The cancer diagnostics company is based in San Diego. It expects its shares will trade on the Nasdaq under the symbol "BIOC."

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.